FIRST HALF RESULTS 2019
Kedrion increased its turnover by 30.8% reaching Euro 364.0 million
Annual General Meeting of Shareholders 2019
Kedrion’s shareholders approve financial statements for fiscal year 2018
ANNUAL RESULTS 2018
Consolidated turnover of Euro 687.9 million, up 14,2%, and adjusted EBITDA of Euro 148.7 million
Kedrion announces FDA Approval for Rhogam® Fill and Finish in Melville
Approval received for aseptic filling, visual inspection, labelling/packaging and associated analytical testing operations
Kedrion announces FDA Approval for its plasma fractionation facility in Melville
Approval received for Fraction II+III, Fraction V and Cryo Paste
Kedrion announces FDA Acceptance of IND Application for 10% Immunoglobulin
U.S. Clinical study in adult patients with Primary Immunodeficiencies will soon be initiated
Closing of antitrust investigation
Released: 21.12.2018 – 17.28 GMTRNS Number: 3510LKedrion in S.p.A. Castelvecchio Pascoli (Lucca, Italy), 21 December 2018 – Kedrion announces that today, 21 December 2018, the Company has been notified of the closing of the investigation opened by the Italian antitrust authority “Autorità Garante della Concorrenza e del Mercato” (AGCM) for a potential anticompetitive conduct by
Results as of 30 September 2018
Consolidated turnover of Euro 438.6 million and adjusted EBITDA of Euro 104.8 million
First half results 2018
Consolidated turnover of Euro 278.3 million and adjusted gross margin of 39.0%